This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We may also share information about your use of our site with analytics partners. Read about cookies in our Cookie Policy. By clicking “Accept”, you are indicating your consent to our use of cookies and policies.

ANGITIA - INNOVATION FOR PATIENTS
Home
About Us
Pipeline
Careers
Media & News
Contact Us

INNOVATION FOR PATIENTS
About us

Founded in 2018, Angitia is a clinical-stage biotechnology company focused on the discovery and development of breakthrough therapeutics that address the key unmet medical needs in serious musculoskeletal diseases. With our team's experience and scientific expertise in novel drug development, Angitia is dedicated to bringing innovative therapies to help patients in need.

Diseases
Degenerative Disc Disease
Osteoporosis
Osteogenesis Imperfecta
Bone Metastasis
Nonunion
Osteoarthritis
Muscle Disorders
We Focus on
Musculoskeletal Diseases
More information
Careers
Become an Angitian! Angitia is a global company with a diverse team.
Our company culture revolves around respect and equality.
We are committed to fostering employee growth and career development.
More‧‧‧‧‧
Media & News
2025.03.18
Angitia Biopharmaceuticals Presents Data from Phase 1/2 Study of AGA111 at 2025 AAOS Annual Meeting
AGA111 treatment resulted in high spinal fusion success rate and improved functional outcomes
More‧‧‧‧‧
2025.01.08
Angitia Biopharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
More‧‧‧‧‧
2024.12.11
Angitia Biopharmaceuticals Announces $120 Million Series C Financing
Financing led by Bain Capital Life Sciences with significant participation from existing and new investors
More‧‧‧‧‧
more news...